San Ramon, CA-February 2, 2009-Nextrials, Inc., a leader in clinical research software and services, is marking its tenth anniversary year by investing part of its 2009 revenue within the pharmaceutical, biotechnology and medical device markets it serves. Between now and June 30, new customers for Nextrials’ award-winning Prism data capture and clinical trial management platform will receive one free database design for a study intended to last at least six months. This generates a significant savings for the user, based on the length and size of the study.
The company’s free database offer comes at a time when clinical trial delays and costs are rising due to increasingly complicated and ambitious protocols. This has sometimes spelled disaster for young biopharmaceutical and medical device firms trying to get a single product to market, and derailed more diverse and long-term programs within Fortune 500 pharmaceutical companies.
“Nextrials has been very fortunate to have been profitable every year since its inception in 1999, and as a result, we are now able to make an investment back into our industry,” noted James Rogers, CEO and co-founder of Nextrials. “In today’s changing economic climate, we recognize that new, potentially life-saving drugs and devices are at risk of being delayed in their development. Offering new customers a free database design is one way we believe we can introduce the cost- and time-saving benefits of electronic data capture to organizations that may still be running paper-based clinical trials or into those organizations that have postponed studies due to the high costs incurred with other EDC vendors. This will, in turn, help researchers experience cost savings and shorten their time-to-market with new products.”
Nextrials’ award-winning Prism melds sophisticated clinical trial management functionality with electronic data capture in a single, integrated package. It is currently used worldwide by biopharmaceutical and medical device R&D teams developing novel treatments and therapeutics.
About Nextrials
Founded by pharmaceutical researchers in 1999, Nextrials offers today’s most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism, its award-winning Electronic Data Capture (EDC) solution, has been used at over 1,000 research sites to streamline the initiation and management of clinical trials. The company is headquartered in the San Francisco Bay area. For more information, visit www.nextrials.com or call 925-355-3000. A podcast by co-founder and CEO James Rogers on the incorporation of electronic health records into the clinical trial process is also available at http://pharmavoice.com/podcasts.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
ACT Brief Episode 1: Placebos, Politics, and the Ethics of Vaccine Trials
August 1st 2025In this pilot episode of the Applied Clinical Trials Brief, we examine the renewed push for placebo-controlled vaccine trials in the US, why experts warn it violates core ethical standards, and how these proposals could jeopardize both participant safety and future innovation.
Cardiff Reports 49% Response Rate With Onvansertib in RAS-Mutated Colorectal Cancer
August 1st 2025In the ongoing Phase II CRDF-004 trial, onvansertib plus standard-of-care showed a 49% confirmed ORR and early PFS benefit in first-line RAS-mutated metastatic colorectal cancer, with a favorable safety profile and dose-dependent efficacy across endpoints.
Unifying Industry to Better Understand GCP Guidance
August 1st 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.